Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome

Seminars in Oncology

Volumn 31, Issue SUPPL. 6, 2004, Pages 12-17

  Stone, Richard M ^a   Gilliland, D Gary ^b   Klion, Amy D ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; ENZYME INHIBITOR; MONOMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; ONCOPROTEIN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG EFFICACY; ENZYME INHIBITION; FLIP1 LIKE 1 GENE; GENE; GENE FUSION; HUMAN; HYPEREOSINOPHILIC SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; DRUG ANTAGONISM; GENETICS;

ENZYME INHIBITORS; HUMANS; HYPEREOSINOPHILIC SYNDROME; MONOMERIC GTP-BINDING PROTEINS; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR;

EID: 2942633369     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.03.035     Document Type: Article

References (36)

1. Fauci A.S., Harley J.B., Roberts W.C., et al. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med. 97:1982;78-92
2. Holland S.M., Gallin J. Disorders of granulocytes and monocytes. Fauci A.S., Braunwald E., Isselbacher K.J., et al. Harrison's Principles of Internal Medicine. (ed 14):1997;351-359 McGraw-Hill, New York, NY
3. Bain B. When is the "idiopathic" hypereosinophilic syndrome eosinophilic leukaemia? Ned Tijdschr Klin Chem. 21:1996;218-220
4. Chusid M.J., Dale D.C., West B.C., et al. The hypereosinophilic syndrome Analysis of fourteen cases with review of the literature. Medicine (Baltimore). 54:1975;1-27
5. Karnak D., Kayacan O., Beder S., et al. Hypereosinophilic syndrome with pulmonary and cardiac involvement in a patient with asthma. CMAJ. 168:2003;172-175
6. Weller P.F., Bubley G.J. The idiopathic hypereosinophilic syndrome. Blood. 83:1994;2759-2779
7. Chang H.W., Leong K.H., Koh D.R., et al. Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood. 93:1999;1651-1657
8. Harris N.L., Jaffe E.S., Diebold J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues Report of the Clinical Advisory Committee meeting, Airlie House, VA, November 1997. J Clin Oncol. 17:1999;3835-3849
9. Simon H.U., Plotz S.G., Dummer R., et al. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med. 341:1999;1112-1120
10. Roufosse F., Schandene L., Sibille C., et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol. 109:2000;540-548
11. Rioux J.D., Stone V.A., Daly M.J., et al. Familial eosinophilia maps to the cytokine gene cluster on human chromosomal region 5q31-q33. Am J Hum Genet. 63:1998;1086-1094
12. Roufosse F., Cogan E., Goldman M. The hypereosinophilic syndrome revisited. Annu Rev Med. 54:2003;169-184
13. Parrillo J.E., Fauci A.S., Wolff S.M. Therapy of the hypereosinophilic syndrome. Ann Intern Med. 89:1978;167-172
14. Bockenstedt P.L., Santinga J.T., Bolling S.F. Alpha-interferon treatment for idiopathic hypereosinophilic syndrome. Am J Hematol. 45:1994;248-251
15. Nadarajah S., Krafchik B., Roifman C., et al. Treatment of hypereosinophilic syndrome in a child using cyclosporine Implication for a primary T-cell abnormality. Pediatrics. 99:1997;630-633
16. Zabel P., Schlaak M. Cyclosporin for hypereosinophilic syndrome. Ann Hematol. 62:1991;230-231
17. Ueno N.T., Zhao S., Robertson L.E., et al. 2-Chlorodeoxyadenosine therapy for idiopathic hypereosinophilic syndrome. Leukemia. 11:1997;1386-1390
18. Fukushima T., Kuriyama K., Ito H., et al. Successful bone marrow transplantation for idiopathic hypereosinophilic syndrome. Br J Haematol. 90:1995;213-215
19. Vazquez L., Caballero D., Canizo C.D., et al. Allogeneic peripheral blood cell transplantation for hypereosinophilic syndrome with myelofibrosis. Bone Marrow Transplant. 25:2000;217-218
20. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 2:1996;561-566
21. Buchdunger E., Cioffi C.L., Law N., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 295:2000;139-145
22. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 348:2003;994-1004
23. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 347:2002;472-480
24. Apperley J.F., Gardembas M., Melo J.V., et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 347:2002;481-487
25. Schaller J.L., Burkland G.A. Case report Rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed. 3:2001;9
26. Ault P., Cortes J., Koller C., et al. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res. 26:2002;881-884
27. Gleich G.J., Leiferman K.M., Pardanani A., et al. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 359:2002;1577-1578
28. Gotlib J., Malone J., DeAngelo D.J., et al. Imatinib mesylate (GLEEVEC) induces rapid and complex hematologic remissions in patients with idiopathic hypereosinophilic syndrome (HES) without evidence of BCR-ABL or activating mutations in C-KIT and platelet-derived growth factor receptor-beta (PDGFR-β). Blood. 100:2002;798a. (abstr)
29. Cools J., DeAngelo D.J., Gotlib J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 348:2003;1201-1214
30. Cortes J., Ault P., Koller C., et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 101:2003;4714-4716
31. Klion A.D., Noel P., Akin C., et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 101:2003;4660-4666
32. Klion A.D., Robyn J.A., Akin C., et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 103:2004;473-478
33. Pardanani A., Reeder T., Porrata L.F., et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 101:2003;3391-3397
34. Griffin J.H., Leung J., Bruner R.J., et al. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci U S A. 100:2003;7830-7835
35. Cools J., Stover E.H., Boulton C.L., et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell. 3:2003;459-469
36. Stone R., Klimek V., Deangelo D., et al. Oral PKC 412 has activity in patients (pts) with mutant FLT3 acute myeloid leukemia (AML) A phase II trial. Proc Am Soc Clin Oncol. 22:2003;563. (abstr)